Almost 11 years after the suit was filed, a Delaware court has dismissed a class action against AstraZeneca over its alleged consumer fraud in the marketing of heartburn medication Nexium.

Superior Court Judge Vivian L. Medinilla said there was just not enough evidence to show that the plaintiffs—a group of four New York-based health care funds—relied on any alleged misrepresentation by AstraZeneca that Nexium was a better drug than the over-the-counter version of Prilosec.